Institution: University of California, Davis
Investigator(s): David Hessl, Ph.D.
Program: Cogmed JM
Background & Aim: Fragile X syndrome (FXS) is caused by a so-called “full mutation” in the fragile X mental retardation 1 (FMR1) gene at Xq27.3 and occurs in an estimated 1 of every 2,500 to 5,000 live births (Hagerman, 2008; Sherman, 2002). Individuals with fragile X syndrome (FXS) demonstrate profound executive function deficits that interfere with learning, socialization and emotion regulation. Extensive research focused on the animal models of FXS show that targeted pharmacological agents can normalize synaptic connectivity and reverse cognitive and behavioral deficits. This translational work has led to multiple national and international controlled trials in humans with FXS now underway. However, in contrast to the heavy focus on medication treatments, there have been no controlled trials to empirically-validate cognitive or behavioral interventions for FXS. The proposed study, the first non-pharmacological controlled trial for FXS, will evaluate the efficacy of Cogmed, a cognitive training program proven to enhance working memory and executive/frontal function in a variety of clinical populations. Demonstration of effective Cogmed training for FXS would represent a major advance in the field, one that may also generalize to other forms of intellectual disability. Furthermore, it is critical to determine whether the targeted pharmacological treatments can accelerate learning and cognitive development. Thus, the validation of Cogmed for FXS will provide a paradigm for testing hypotheses focused on combined efficacy of medication and cognitive training. The study aim is to evaluate the efficacy of Cogmed to enhance working memory and executive functioning in patients with FXS in a randomized, double-blinded, and placebo-controlled study.
Population & Sample Size: N = 110 individuals with FXS, ages 8 – 18 years
Design: Randomized, Placebo controlled, Double-blinded, Test-retest, 3 Month Follow Up